Isomorphic Labs vs Schrödinger (2026)
The most cited name in computational biology against the most established one, and the comparison is uncomfortable for the newer company. Isomorphic Labs descends from AlphaFold and released a unified drug design engine spanning structure, binding, affinity and antibody modelling, with named partnerships that tell you what working with it involves. But there is no software to license, no interface to call, no published method behind the commercial engine and no molecule in a human being yet. Schrodinger licenses physics based simulation software any research organisation can run, with methods published and independently benchmarked over decades and an asset originated on the platform in late stage development. If you are choosing a platform to use, only one of these can be used. If you are choosing a partner to bet on, the newer one has the more interesting lineage and the shorter track record.
- The lineage is the strongest in structure prediction and the engine unifies structure, ligand binding, affinity and antibody interaction modelling in a single system rather than a chain of tools.
- Deal shape is public and specific, with named multi target discovery collaborations that tell a buyer what a partnership with this company actually looks like.
- Structurally the oversight is the pharmaceutical partner's, since designs generated by the engine enter a partner's own development process rather than an internal pipeline with no external check.
- The methods are published and independently benchmarked across a large peer reviewed literature, so a chemist can evaluate the approach rather than take a demonstration on trust.
- It is licensed software with real deployment disclosure, so an organisation can run it internally, against a company with no software to license, no interface to call and no self service route of any kind.
- A molecule originated on this platform has reached late stage clinical development, where the alternative has never put a molecule into a human being.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Isomorphic Labs and Schrödinger are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Isomorphic Labs | Schrödinger |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2021 | Not recorded |
| Headquarters | London, United Kingdom | New York, NY |
| Website | isomorphiclabs.com | schrodinger.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Isomorphic Labs its top capability grade on AI Centrality. Set against Schrödinger, Isomorphic Labs grades higher on AI Centrality. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Schrödinger its top capability grade on several axes, including Model and Technology Transparency, Clinical and Operational Evidence and AI Governance and Bias Disclosure. Set against Isomorphic Labs, Schrödinger grades higher on several axes, including Model and Technology Transparency, Clinical and Operational Evidence and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Isomorphic Labs or Schrödinger?
On the axes where the AI Health Index separates them, Isomorphic Labs grades higher on AI Centrality, and Schrödinger grades higher on several axes, including Model and Technology Transparency, Clinical and Operational Evidence and Security Certifications and Trust Center. Schrödinger leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Isomorphic Labs and Schrödinger differ most?
The widest separation the AI Health Index records between Isomorphic Labs and Schrödinger is on AI Centrality, where Isomorphic Labs grades A and Schrödinger grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Isomorphic Labs and Schrödinger grade the same?
The AI Health Index grades Isomorphic Labs and Schrödinger the same on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Isomorphic Labs and Schrödinger not disclosed?
At the last review, at least one of Isomorphic Labs and Schrödinger published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Isomorphic has the sharpest disclosure gap in this category and it is notable because of the lineage: the AlphaFold papers were published and benchmarked, while the commercial engine built on that lineage has no published method, no benchmark and no external validation. No molecule from the platform has entered a human, with first in human work targeted for the end of 2026, so its evidence position is a statement of stage rather than of quality.
No attestation, trust centre or security page was located for it. Schrodinger holds the lowest AI centrality grade in this category because the platform is physics based simulation rather than learned models, which is descriptive rather than critical.